Advertisement
Advertisement
U.S. Markets open in 9 hrs 8 mins
Advertisement
Advertisement
Advertisement
Advertisement

Moleculin Biotech, Inc. (MBRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.0900+0.0200 (+1.87%)
At close: 04:00PM EDT
1.0700 -0.02 (-1.83%)
After hours: 04:31PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.0700
Open1.0500
Bid1.0700 x 1100
Ask1.1100 x 1800
Day's Range1.0500 - 1.1600
52 Week Range0.9280 - 2.8500
Volume33,071
Avg. Volume102,064
Market Cap31.181M
Beta (5Y Monthly)1.80
PE Ratio (TTM)N/A
EPS (TTM)-0.6410
Earnings DateNov 09, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.67
  • Benzinga

    Moleculin Biotech's Potential Antiviral Compound Selected For NIAID-Funded Animal Studies

    Moleculin Biotech Inc (NASDAQ: MBRX) announced that its WP1096 molecule would be evaluated in animal studies by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Moleculin studies WP1096 as a novel potential therapy for a broad spectrum of viruses, including arenaviruses. WP1096 is a compound within the WP1122 portfolio. WP1122 molecule is a prodrug of 2-deoxy-D-glucose (2-DG), and 2-DG has been approved outside the U.S. for use as a tr

  • PR Newswire

    Moleculin Biotech WP1122 Portfolio Compound, WP1096, Selected for NIAID-Funded Animal Studies as Novel Potential Antiviral

    Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced its WP1096 molecule (a part of its WP1122 portfolio of D-glucose and D-mannose antimetabolites) will be evaluated in animal studies through the preclinical services offered by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. W

  • PR Newswire

    Moleculin Biotech to Present at the Virtual Investor Innovations in Acute Myeloid Leukemia (AML) Spotlight Event

    Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter V. Kemp, Founder, President, CEO and Chairman, and Wolfram C. M. Dempke, MD, PhD, MBA, European Chief Medical Officer of Moleculin will participate in the Virtual Investor Innovations in Acute Myeloid Leukemia Spotlight Event on Wednesday, September 28, 2022 at 11:00 AM ET.

Advertisement
Advertisement